NASDAQ:NCNA - NuCana Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $23.10 +0.21 (+0.92 %) (As of 07/23/2018 06:00 AM ET)Previous Close$23.10Today's Range$22.51 - $23.8352-Week Range$9.32 - $32.00Volume46,576 shsAverage Volume24,752 shsMarket Capitalization$734.83 millionP/E Ratio-21.79Dividend YieldN/ABetaN/A Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematological malignancies. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. Receive NCNA News and Ratings via Email Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:NCNA CUSIPN/A Webwww.nucana.com Phone44-13-1357-1111 Debt Debt-to-Equity RatioN/A Current Ratio34.95 Quick Ratio34.95 Price-To-Earnings Trailing P/E Ratio-21.79 Forward P/E Ratio-20.63 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.78 per share Price / Book6.11 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees20 Outstanding Shares31,810,000Market Cap$734.83 NuCana (NASDAQ:NCNA) Frequently Asked Questions What is NuCana's stock symbol? NuCana trades on the NASDAQ under the ticker symbol "NCNA." How were NuCana's earnings last quarter? NuCana PLC (NASDAQ:NCNA) posted its quarterly earnings results on Wednesday, May, 23rd. The company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.06. View NuCana's Earnings History. What price target have analysts set for NCNA? 4 brokerages have issued twelve-month target prices for NuCana's stock. Their forecasts range from $23.00 to $25.00. On average, they anticipate NuCana's stock price to reach $24.00 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Ratings for NuCana. What is the consensus analysts' recommendation for NuCana? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of NuCana's key competitors? Some companies that are related to NuCana include The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Endo International (ENDP), Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA) and Xencor (XNCR). Who are NuCana's key executives? NuCana's management team includes the folowing people: Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 72)Mr. Hugh S. Griffith, Founder, CEO & Director (Age 50)Mr. Donald Munoz, Chief Financial Officer (Age 49) When did NuCana IPO? (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. Has NuCana been receiving favorable news coverage? Headlines about NCNA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuCana earned a coverage optimism score of 0.10 on Accern's scale. They also assigned headlines about the company an impact score of 46.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are NuCana's major shareholders? NuCana's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (2.06%). View Institutional Ownership Trends for NuCana. Which institutional investors are buying NuCana stock? NCNA stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co.. View Insider Buying and Selling for NuCana. How do I buy shares of NuCana? Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NuCana's stock price today? One share of NCNA stock can currently be purchased for approximately $23.10. How big of a company is NuCana? NuCana has a market capitalization of $734.83 million. The company earns $-29,750,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. NuCana employs 20 workers across the globe. How can I contact NuCana? NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-13-1357-1111. MarketBeat Community Rating for NuCana (NASDAQ NCNA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 102 (Vote Outperform)Underperform Votes: 76 (Vote Underperform)Total Votes: 178MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: What does EPS mean?